Floatz logo

hx009

Relapsed/Refractory Lymphoma

Hangzhou Hanx Biopharmaceuticals, Ltd.monoclonal_antibodyPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

288 Active assets in the Relapsed/Refractory Lymphoma cohort.

Asset / SponsorPhaseRating
VINBLASTINE
Intensity Therapeutics, Inc.
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
The Lymphoma Academic Research Organisation
Phase 4BBB
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
BLEOMYCIN
Shandong Provincial Hospital
Phase 4BB
Cyclophosphamide
Beth Israel Deaconess Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

hx009 is also rated in:

cancerDormant
CCC
Indicative ·
53 / 100
View asset →
biliary tract cancerDormant
CC
Indicative ·
43 / 100
View asset →
melanomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →